Edge Therapeutics

About:

Edge Therapeutics, a biotechnology company, transforms FDA-approved drugs into therapies that address unmet acute neurological conditions.

Website: http://edgetherapeutics.com

Top Investors: Hercules Capital, Sofinnova Investments, NJEDA, Venrock, New Leaf Venture Partners

Description:

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.